Fluticasone Furoate + Vilanterol Suppliers & Bulk Manufacturers
Available Forms: Powder For Inhalation(DPI/MDI)
Available Strengths: 92 mcg Fluticasone furoate / 22 mcg Vilanterol; 184 mcg Fluticasone furoate / 22 mcg Vilanterol
Reference Brands: Breo Ellipta®(US), Relvar Ellipta® (EU)
Category:
Respiratory Disorder
Fluticasone furoate + Vilanterol, sold as Breo Ellipta® (U.S.) and Relvar Ellipta® (EU), is a once-daily inhalation therapy for asthma and COPD. It combines anti-inflammatory and bronchodilator action in strengths like 92/22 mcg and 184/22 mcg, delivered via the Ellipta® DPI. A top choice in respiratory care and pharma exports.
Fluticasone furoate + Vilanterol is available in Powder For Inhalation(DPI/MDI)
and strengths such as 92 mcg Fluticasone furoate / 22 mcg Vilanterol; 184 mcg Fluticasone furoate / 22 mcg Vilanterol.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Fluticasone furoate + Vilanterol is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Fluticasone furoate + Vilanterol can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Fluticasone furoate and Vilanterol is a powerful once-daily combination therapy used for the long-term treatment of asthma and chronic obstructive pulmonary disease (COPD). Marketed as Breo Ellipta® in the U.S. and Relvar Ellipta® in the EU, this inhalation powder combines Fluticasone, a corticosteroid that reduces inflammation, with Vilanterol, a long-acting beta-agonist (LABA) that relaxes airway muscles. Available in 92/22 mcg and 184/22 mcg strengths via the Ellipta® DPI, it offers 24-hour symptom control. Ideal for pharma B2B and export markets, this therapy enhances adherence and delivers effective respiratory relief with convenient once-daily dosing.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing